FDA Expands Pluvicto Into PSMA-Positive Hormone-Sensitive Prostate Cancer
The FDA has approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan), used in combination with an androgen-receptor pathway inhibitor, for adults with PSMA-positive metastatic androgen pathway modulation-naive or -sensitive prostate cancer — commonly described as…
